1、時(shí)間：二O二一年七月二十九日甲狀腺功能亢進(jìn)與肝損害之馬矢奏春創(chuàng)作時(shí)間：二O二一年七月二十九日甲狀腺功能亢進(jìn)癥（甲亢）所引起的肝臟損害在臨床上相當(dāng)罕 見(jiàn).據(jù)Gurlek A （1）等觀察，60.5 %的甲亢病人在確診原發(fā)病時(shí)被 發(fā)現(xiàn)至少有一項(xiàng)肝功能異常，而在臺(tái)灣進(jìn)行的一項(xiàng)前瞻性研究（Huang. MJ等）中，這個(gè)比例更是高達(dá) 75.8 % （ 2）.本文就甲亢 合并肝臟損害作一綜述.甲狀腺激素對(duì)肝臟的影響甲狀腺激素和肝臟之間關(guān)系密切.血清甲狀腺激素濃度增高，對(duì)肝臟功能和膽汁代謝都可發(fā)生一定的影響.植物試驗(yàn)證實(shí)（3,4）,甲狀腺激素可使肝臟重量減輕，肝糖原含量下降，氧耗量增加，具增加肝臟氧耗量的作

2、用僅次于對(duì)心臟和橫膈膜.血清中過(guò)多的甲狀腺激素可顯著降低細(xì)胞色素P450、谷胱甘肽水平及谷胱甘肽-S-轉(zhuǎn)移酶活性，從而改變肝內(nèi)相關(guān)酶的活性（5,6 ） .T4能使 -磷酸甘油 脫氫酶（GPD）的活力增強(qiáng).甲狀腺激素可抑制肝內(nèi)膽固醇的發(fā)生，增進(jìn)肝內(nèi)膽固醇從膽道排泄或轉(zhuǎn)化為膽汁酸，從而使血清膽固醇降低干擾膽汁酸代謝.另外，甲狀腺激素還能影響膽汁中膽汁酸鹽的組 成.研究發(fā)現(xiàn)，正常鼠膽汁中的?；悄懼嵴寄懼岬?0%左右，給予甲狀腺素后，牛磺膽汁酸所占的比例可上升至60%-80 %.甲亢時(shí)肝臟的改變甲亢引起的肝臟損害大都呈亞臨床狀態(tài).不外，少數(shù)病人也可時(shí)間：二O二一年七月二十九日時(shí)間：二 O 二一年七

3、月二十九日呈現(xiàn)黃疸、腹水、凝血酶原明顯延長(zhǎng)、肝硬化等嚴(yán)重情況. 這一情況多發(fā)生于甲亢控制欠安或有心衰、嚴(yán)重感染等患者. 至于甲亢嚴(yán)重度與肝損是否存在正相關(guān), 目前還有所爭(zhēng)論.在血生化檢查方面, 甲亢肝臟損害患者主要暗示為ALT、 AST、ALR 丫 -GT和膽紅素升高，血清白卵白下降（1,2 ）.其中，以ALP升高最為明顯,ALT 次之 . 白卵白的下降與基礎(chǔ)代謝率和病程相關(guān).不外 , 鑒于甲亢患者往往骨代謝旺盛, 成骨細(xì)胞和破骨細(xì)胞活性增加 , 且體外試驗(yàn)證實(shí)甲狀腺激素有直接使骨吸收的作用 , 因此 , 升高的 ALP 不單僅來(lái)自肝臟, 也來(lái)自骨骼, 它對(duì)肝臟的評(píng)價(jià)意義可能不如ALT.在嚴(yán)重

4、肝臟損害時(shí),由于病人血中甲狀腺激素結(jié)合卵白濃度的明顯改變, 總 T4 水平其實(shí)不能如實(shí)反映甲狀腺功能狀態(tài), 此時(shí) ,應(yīng)監(jiān)測(cè)游離T4 和甲狀腺安慰素（ TSH） 以正確評(píng)估甲狀腺功能（ 7） .甲亢病人肝臟損害的病理改變多種多樣, 根據(jù)尸檢結(jié)果, 年夜體上可分為三年夜類(lèi)： 1、 急性退行性肝損害如顯著脂肪變性 , 中心性或局灶性肝壞死；2、局部或彌漫性萎縮；3、硬變 . 這三種改變可同時(shí)存在. 其中以脂肪浸潤(rùn)最為罕見(jiàn) .Beaver 等人的研究標(biāo)明 , 甲亢患者呈現(xiàn)肝臟脂肪浸潤(rùn)的比例可高達(dá)87.8 . 在病理切片上 , 可呈現(xiàn)肝細(xì)胞氣球樣改變, 肝細(xì)胞壞死, 殘余肝細(xì)胞膽色素顆粒冷靜,肝小葉中央

5、灶性壞死, 結(jié)締組織增生 , 新生毛細(xì)血管呈現(xiàn), 局部淋巴細(xì)胞、單核細(xì)胞浸潤(rùn) , 毛細(xì)膽管及Kupffer 細(xì)胞增生等（ 8） .發(fā)病機(jī)制肝臟在甲狀腺激素的轉(zhuǎn)運(yùn)、代謝、貯存、分泌以及活性的發(fā)揮過(guò)程中都起著重要的作用 , 而甲狀腺激素水平對(duì)維持肝臟正常功能及膽汁正常代謝也是不成缺少的 . 雖然甲亢引起肝臟損害的機(jī)制目前仍不是很清楚, 但高水平的甲狀腺激素在肝臟損害的發(fā)病中所起的作用是毋庸置疑的（7）.甲亢患者高甲狀腺激素（T3、T4）通過(guò)以下可能途徑影響肝功能： （ 1 ）高基礎(chǔ)代謝率. 它使內(nèi)臟組織耗氧量增加 , 而與此同時(shí), 內(nèi)臟動(dòng)脈血流其實(shí)不增加 , 造成相對(duì)缺氧狀態(tài)尤其是肝小葉中央?yún)^(qū)域細(xì)

6、胞供氧相對(duì)缺乏引起該區(qū)域壞死, 使谷丙轉(zhuǎn)氨酶（ ALT） 升高 , 這與臨床上甲亢肝損病人肝穿刺活檢結(jié)果相一致（ 8 ） . （ 2 ）由于甲狀腺激素年夜量分泌, 分解代謝亢進(jìn), 肝糖原耗損 , 必需氨基酸和維生素消耗過(guò)多 , 造成負(fù)氮平衡, 卵白質(zhì)缺乏,營(yíng)養(yǎng)不良而使肝細(xì)胞變性，造成肝內(nèi)膽汁瘀積而引起 丫 -GT和堿性磷酸酶（AL?升高.植物試驗(yàn)證實(shí)（12）,甲狀腺激素除可引起與劑量有依賴(lài)關(guān)系的肝糖原含量降低外, 還同時(shí)引起劑量依賴(lài)性的肝胞液糖皮質(zhì)激素受體（GCR數(shù)目增多，Gurlek等的研究進(jìn)一步證 實(shí)，甲亢患者ALP和丫-GT升高的比例分別高達(dá)44.2 %和14%,不外由于甲亢患者骨代謝異

7、常也可引起ALP 升高 , 一定水平上削弱了評(píng)價(jià)肝損的可靠性（2） . （ 3 ）甲狀腺激素直接作用于肝臟, 包括抑制肝臟中葡萄糖醛酸基轉(zhuǎn)移酶, 使膽紅素和葡萄糖醛酸結(jié)合障礙,進(jìn)而影響膽紅素從膽汁中排泄, 招致血中膽紅素升高（ 2,7 ） .隨著免疫學(xué)的飛速進(jìn)展, 自身免疫機(jī)制在甲亢肝損中的位置日益引起人們的關(guān)注. 目前認(rèn)為 , 甲狀腺疾病與肝臟疾病有著共同的發(fā)病基礎(chǔ) , 即自身免疫 . 研究發(fā)現(xiàn) , 丙肝病毒感染、干擾素治療等都可誘發(fā)甲亢（13,14,15 ） . 甲亢病人往往存在特異性免疫調(diào)節(jié)缺陷 ,其抑制性T細(xì)胞功能減弱，B細(xì)胞和巨噬細(xì)胞數(shù)目增多（16,17）.95年 ,Cathebra

8、s PJ 等報(bào)道了第 1 例甲亢引起的肉芽腫性肝炎, 后者的進(jìn)展與甲亢的嚴(yán)重水平平行發(fā)展, 經(jīng)抗甲狀腺藥物治療后好轉(zhuǎn)（ 18） . 從分子水平來(lái)看,Graves 病等甲狀腺疾病和肝炎都存在著細(xì)胞因子的異常, 它們反應(yīng)了特定人群對(duì)某種疾病的易感性 , 比如 ,目前已經(jīng)證實(shí)，HLA-A11和HLA-DR4陽(yáng)性的病人，甲亢合并肝損的比例可能更高（ 8,19 ） . 這為將來(lái)甲亢肝損易感人群的防治提供了新的思路 .甲亢引起肝損及其嚴(yán)重水平與甲亢引起的其它并發(fā)癥也有密切關(guān)系 , 如心功能不全, 休克等 . 通過(guò)病例分析,Fong TL 等人（ 20）發(fā)現(xiàn)，甲亢和/或甲亢合并CHF患者都可呈現(xiàn)嚴(yán)重的肝功能

9、異常，包括重度黃疸、 凝血酶原時(shí)間延長(zhǎng)等. 而合并心衰者, 呈現(xiàn)肝功能異常的比例遠(yuǎn)比無(wú)并發(fā)癥的甲亢病人多 . 國(guó)內(nèi)資料也證實(shí)了這一點(diǎn)（ 21） .另外 , 甲亢可加劇其它肝損藥物的毒性作用 , 包括酒精、 氟烷等 .這可能與甲亢引起細(xì)胞色素P450、谷胱甘肽水平及谷胱甘肽-S-轉(zhuǎn)移酶活性的顯著下降有關(guān)（ 5,6 ） .診斷甲亢肝損有時(shí)與甲亢合并病毒性肝炎、 抗甲狀腺藥物引起的藥物性肝炎不容易區(qū)分. 甲亢合并病毒性肝炎主要有以下幾種情況：（ 1 ） 病毒性肝炎和甲亢無(wú)關(guān), 相互自力存在. 這一類(lèi)情況最為多見(jiàn)；（ 2 ） 病毒性肝炎引起甲亢 . 這是因?yàn)椴《拘愿窝字饕ㄟ^(guò)免疫機(jī)制攻擊人體 , 與甲

10、亢存在著共同的發(fā)病基礎(chǔ), 尤其是丙肝病毒感染. 流行病學(xué)觀察發(fā)現(xiàn)（ 9 ） , 慢性丙肝病毒感染的女性患者與甲狀腺自身免疫性疾病的發(fā)生率正相關(guān), 其中甲狀腺機(jī)能亢進(jìn)占了相當(dāng)年夜的比例（ 7 ） ； （ 3 ）干擾素治療的肝炎患者. 由于干擾素使機(jī)體免疫功能紊亂 , 即使停藥后 , 仍有可能呈現(xiàn)甲亢癥狀（ 10,11 ） . 兩者的鑒別要點(diǎn)： 1、 甲亢合并病毒性肝炎患者多有明確的流行病學(xué)史 , 如輸血等； 甲亢所致的肝損多見(jiàn)于未進(jìn)行正規(guī)抗甲狀腺藥物治療或呈現(xiàn)各種并發(fā)癥的患者.2 、甲亢合并病毒性肝炎患者除甲亢的癥狀外, 消化系統(tǒng)食欲不振、厭食油膩等肝炎癥狀明顯, 而甲亢患者肝損癥狀一般較輕微.

11、3 、甲亢合并病毒性肝炎患者血清中肝炎病毒標(biāo)識(shí)表記標(biāo)幟物陽(yáng)性, 具有確診價(jià)值； 同時(shí) , 這一類(lèi)患者肝功能血清酶滴度也明顯比甲亢肝損患者高 .4 、 治療上 , 一為保肝藥物為主, 一為抗甲狀腺藥物為主.另一需要鑒另外是甲亢治療過(guò)程中呈現(xiàn)的藥物性肝損 . 后者多有明確的抗甲狀腺藥物服用史 , 一般在治療一個(gè)月后發(fā)生, 往往呈一過(guò)性；肝損癥狀也比力輕微, 但常合并呈現(xiàn)皮膚搔癢、皮疹等過(guò)敏現(xiàn)象；血生化檢查除酶學(xué)異常外, 還可見(jiàn)嗜酸粒細(xì)胞升高；停藥后肝功能可恢復(fù)正常, 再用再發(fā) .由于誤診其實(shí)不是少見(jiàn), 尤其是甲亢肝損與甲亢合并病毒性肝炎這兩種情況, 而它們?cè)谥委熒夏暌共幌嗤?, 因此 , 臨床醫(yī)生

12、在下診斷前必需對(duì)病史作綜合分析.治療與預(yù)后由于體內(nèi)甲狀腺激素分泌過(guò)多是肝臟損害的主要原因 , 因此 ,有效地控制甲狀腺功能亢進(jìn)是預(yù)防、治療肝損的關(guān)鍵 . 臨床上以?xún)?nèi)科藥物治療為主. 慣例治療方案： （ 1 ）注意休息 , 攝入足夠的營(yíng)養(yǎng).（ 2 ）停用一切肝損藥物 . （ 3 ）抗甲狀腺藥物. 經(jīng)常使用者為硫脲類(lèi)中的甲基及丙基硫氧嘧啶和咪唑類(lèi)中的他巴唑及甲亢平. 丙基硫氧喀咤是甲亢合并肝臟損害的首選藥物，開(kāi)始可用100750mg，每8小時(shí)一次 , 一旦病情獲得控制 , 宜逐漸減少劑量, 摸索一個(gè)合適的維持量.（4） （3-受體阻滯劑.B -受體阻滯劑如心得安能阻抑T4轉(zhuǎn)化為T(mén)3, 減少氧耗量與

13、負(fù)氮平衡, 同時(shí)減慢心率, 減輕交感神經(jīng)興奮癥狀但不影響病程.劑量可用1020mg, 一日三次.暫不宜硫月尿類(lèi)藥物治療的病人 , 可先用此類(lèi)藥物控制癥狀, 待病情控制后再選用其它手段治療.（5）保肝治療.可同時(shí)服用維生素B族和維生素C族.（6）由于免疫因素在甲亢肝損的發(fā)病也起了重要作用 , 因此 , 對(duì)較為嚴(yán)重的肝損病人, 也可短時(shí)間應(yīng)用糖皮質(zhì)激素治療 （ 18 ） , 至于輕中度肝損患者 , 是否應(yīng)用糖皮質(zhì)激素尚有爭(zhēng)論. （ 6）嚴(yán)格控制心衰、感染等并發(fā)癥.甲亢肝損患者若診斷及時(shí), 治療積極 , 預(yù)后良好 . 一般在正規(guī)抗甲狀腺治療36 個(gè)月后 , 肝功能全部恢復(fù)正常.Arch Intern

14、 Med. 1984 Sep;144（9）:1764-5.PTU 致彌漫的間質(zhì)性肺炎：咳嗽、勞力性呼吸困難、低氧血癥發(fā)生于一Graves' 病患者 PTU（ 300 mg/day ）治療6 月后和另一 Graves'病患者PTU （300 mg/day ）治療3周后,胸片和時(shí)間：二 O 二一年七月二十九日時(shí)間：二O二一年七月二十九日支氣管鏡下肺活檢顯示彌漫的間質(zhì)性肺炎 .植物血凝素轉(zhuǎn)化 淋巴細(xì)胞受PTU高度安慰.停用PTU予以強(qiáng)的松龍治療后癥 狀和 體征獲得改善.Propylthiouracil-induced diffuse interstitial pneumonitis.

15、Miyazono K, Okazaki T, Uchida S, Totsuka Y, Matsumoto T, Ogata E, Terakawa K, Kurihara N, Takeda T.1. 1947年，首次報(bào)道PTU的肝毒性副作用.Livingston HJ, Livingston SF. 1947 Agranulocytosis and hepatocellular jaundice. JAMA. 135:422- 425.2 Characteristics of patients withpropylthiouracil-associated hepatotoxicityAl

16、l cases (nSurvivors (n Fatalities (n=28)= 21)= 7)27.9 17.124.7 15.537.3 19.225/319/24/1426 ±199424 立00433 蟲(chóng)163.6 3.53.7 3.23.6 4.52 (7.1)2 (9.5)0 (0)5 (17.9)4 (19.0)1 (14.3)21 (75.0)15 (71.4)6 (85.7)Age, yr (mean S D)Females/males (no.)Propylthiouracil dose at presentation with hepatotoxicity,

17、mg/day (mean SD) ±Months of continuous propylthiouracil therapy before hepatotoxicity (mean SD) ±Baseline liver function tests, no. of cases (%)NormalAbnormalNot reporteds exact te st.Table 4. Prevalence of thyroid function test abnormalities and management of hyperthyroidism at presentati

18、on with propylthiouracil hepatotoxicitySurvivors (n = 22)Fatalities (n = 7)Thyroid function tests, no. of cases (%)Hyperthyroid5 (19)2 (28.6)Normal8 (38.1)1 (14.3)Hypothyroid1 (4.8)0 (0)Not reported8 (38.1)4 (57.1)Treatment of hyperthyroidism, Patients may have received more than one form of therapy

19、.2P < 0.05 compared to fatalities, by Fisher no. of cases (%)Radioactive iodine12 (54.5)No patient who died received 131I. The timing of 131Iranged from 1 - 15 weeks (mean, 32 士 8 days) afterpresentation with hepatotoxicity. Ten of the 12 patients who received 131I0 (0)Propranolol10 (45.5)4 (57.1

20、)Methimazole3 (13.6)0 (0)Oral iodide4 (18.2)1 (14.3)Thyroidectomy1 (4.5)0 (0)Not reported7 (31.8)3 (42.9)時(shí)間：二O二一年七月二十九日時(shí)間：二O二一年七月二十九日therapy were treated before the hepatic function test abnormalitiesresolved.據(jù)估計(jì)ATD相關(guān)的肝毒性發(fā)生率小于0.5%; PTU相關(guān)的肝毒性發(fā)生于各個(gè)年齡；女性居多；發(fā)生肝毒性的PTU劑量與療程范圍甚廣；肝活檢示非特異的肝細(xì)胞壞死；ATD致肝毒性的機(jī)制尚不明

21、了，部份是由于機(jī)體對(duì)PTU發(fā)生免疫反應(yīng).在迸發(fā)性肝功能衰竭中 , 一些早期預(yù)后因素與生存率低(<20%)有關(guān) , 其包括病人年齡(<11 和 >40 yr) 、腦病發(fā)生前黃疸延續(xù)時(shí)間(>7 days)、血清膽紅素濃度(>300 mol/L)、凝血酶原時(shí)間(>50 s).在對(duì)PTU所致肝毒性病人進(jìn)行嚴(yán)密的臨床和實(shí)驗(yàn)室觀察的基礎(chǔ)上(因?yàn)橥Ｓ肞TU后肝功能衰竭仍可發(fā)展)，應(yīng)考慮肝移植.腦病、低凝血酶原血癥、肝腎綜合征對(duì)肝移植晦氣. 血漿置換、用血流灌注法血透可有效地糾正凝血障礙和腦病, 為恢復(fù)肝功能或進(jìn)行肝移植締造時(shí)機(jī) .因 TT4 受甲狀腺激素結(jié)合卵白、血清膽紅

22、素(降低T4 與甲狀腺激素結(jié)合卵白的親和)、甲狀腺功能正常性病變綜合征的影響 , 所以檢測(cè) FT4 才華真正反映患者甲狀腺功能狀況.病人接受 131I 治療比未接受治療者較少發(fā)生嚴(yán)重的肝毒性 . 治療應(yīng)在做腹部CT (如果需要碘造影劑)或因甲狀腺毒癥需碘化物治療前進(jìn)行.碘化物可在131I治療1周后服.心得安可用于控制甲亢 癥狀；肝酶正常后也可使用MMI.肝毒性呈現(xiàn)后可獨(dú)自使用碘化物.在大都病人，114 mg碘化物在7- 14天內(nèi)對(duì)甲狀腺激素的發(fā)生最年夜的抑制，作用繼續(xù)150天.但通常與ATD合用，碘化物也可加重甲狀腺毒癥狀況.繼往肝功能正常的甲亢病人中，高達(dá)72%者至少陪伴1個(gè)肝酶指標(biāo) 的升高

23、.以AKP升高最罕見(jiàn)，轉(zhuǎn)氨酶升高是由于甲狀腺毒癥招致的 肝臟的氧耗增加，而肝血流代償缺乏.已報(bào)道MMI所致肝毒性21例，死亡3例（14% ,死亡率與PTU比力 無(wú)顯著不同.MMI所致肝毒性患者的肝活檢更多暗示為膽汁淤積.Table 5. Summary of recommendations for management of propylthiouracil hepatotoxicity1 .盡管肝酶研究無(wú)法預(yù)測(cè)哪些病人將發(fā)生肝毒性，但肝酶基值的測(cè)定可作為治療過(guò)程中發(fā)生月干臟疾病的參考 . Although liver enzyme studies may not predict which

24、patients will develop hepatotoxicity, baseline studies may serve as a reference value if signs of liver disease develop during the course of therapy.2 .治療過(guò)程中呈現(xiàn)明顯的肝酶異常時(shí)，需停用PTU,并尋找引起肝并的潛在因 H .Significant liver enzyme abnormalities detected during the course of therapy require prompt discontinuation of

25、 propylthiouracil as well as a search for any other potential sources of liver disease.3 .懷疑有肝毒性的病人需密切隨訪 ，因?yàn)楦喂δ苷系K在停用 PTU后仍有進(jìn)展.Patients with suspected hepatotoxicity require close clinical follow-up because liver dysfunction can progress despite discontinuation of propylthiouracil.4 .對(duì)是否需要肝移植的早期認(rèn)識(shí)可能提

26、高生存.Early recognition of the need for livertransplantation may improve survival.5 .甲狀腺狀態(tài)的判斷需結(jié)合臨床檢查和FT4水平，因?yàn)楦吣懠t素血癥可負(fù)向干擾 TT4水平.Thyroidal status must be determined by a combination of clinical examination and free T 4 levels because hyperbilirubinemia can adversely affect the interpretation of total T

27、4 levels.6 .進(jìn)一步用放射性碘治療甲亢，隨后配以碘化物可能緩解甲亢的惡化 .Prompt treatment of the underlying thyroid disease with radioactive iodine followed by iodide may diminish the chance of clinical deterioration from persistent hyperthyroidism.7 .即使肝酶恢復(fù)正常仍不能再次用PTU,因?yàn)樗母味拘源嬖谧陨砻庖叩馁x 性.Propylthiouracil should not be reinstitute

28、d even after the resolution of liver enzyme abnormalities due to the possible autoimmune nature of its hepatotoxicity.甲亢相關(guān)的肝功能基值的異常沒(méi)有需要成為運(yùn)用ATD的禁忌癥，現(xiàn)有的資料無(wú)法證實(shí)肝功能基值異常的病人更易發(fā)生PTU所致的肝毒性.由于自身免疫因素介入PTU所致的肝毒性、肝毒性情況在再次用PTU后又呈現(xiàn)，所以肝毒性治療后和肝移植后仍不能用PTU.fFifty Years of Experience with Propylthiouracil-AssociatedHep

29、atotoxicity: What Have We Learned?1Katherine V. Williams, Sunil Nayak, Dorothy Becker, JorgeReyes and Lynn A. BurmeisterThe Journal of Clinical Endocrinology & Metabolism Vol. 82,No. 6 1727-17333.Toxic hepatitis (primarily with propylthiouracil) and cholestatic jaundice (primarily with methimazo

30、le) are fortunately uncommon.150 Toxic hepatitis can be severe or fatal, but the incidence of serious liver complications is so low that routine monitoring of function tests has not been advised.151,152 Liver transplantation has been used with success in several patients 152.1.IFN-a induces thyroid

31、dysfunctionin 3 to 14%of all treatedpatients with chronic hepatitis C, leading to hypothyroidism, hyperthyroidism, or thyroiditis. In a few patients, thyroid disease will develop in the absence of antithyroid antibodies, a scenario that suggests a nonimmune-mediated mechanism.:Am J Gastroenterol. 20

32、01 Jan;96(1):165-9.Related Articles,Links國(guó) The incidence and clinical characteristics of symptomatic propylthiouracil-induced hepatic injury in patients with hyperthyroidism:a single-centerretrospective study.Kim HJ, Kim BH, Han YS, Yang I, Kim KJ, Dong SH, Kim HJ, Chang YW, Lee JI, Chang R.Departme

33、nt of Internal Medicine, Kyung Hee University College of Medicine,搜索引擎優(yōu)化 ul, Korea.時(shí)間：二O二一年七月二十九日時(shí)間：二 O 二一年七月二十九日OBJECTIVES: Although symptomatic propylthiouracil (PTU)-induced hepatic injury is known to be rare, there have been few reports about its exact incidence in patients with hyperthyroidism.

34、 Wetried to evaluate its incidence in a single center and its clinical course.METHODS: Medical records of 912 hyperthyroid patients who had been diagnosed between March 1990 and December 1998 were reviewed about clinical characteristics, management, and laboratory findings. Symptomatic PTU-induced h

35、epatic injury was defined as the development of jaundice or hepatitis symptoms with at least a 3-times elevation of liver function tests (LFT) without other causes. RESULTS: Four hundred ninety-seven patients (age 42.6+/-10.7 yr,male/female 140/357) were included. Clinically overt hepatitis develope

36、d in six patients (1.2%; age, 43.7 +/14.8 yr; male:female ratio, 3:3) between 12 and 49 days after PTU administration. Jaundice and itching developed in five patients, fever in two, rash in two, and arthralgia in one. Bilirubin, ALT, and ALPincreased in five, four, and six patients, respectively (29

37、3 +/-288 micromol/L, 143 +/- 111 U/L, and 265 +/- 81 U/L;normal, < 117 U/L).The type of hepatic injurywascholestatic in three,hepatocellular in one, and mixedin two patients. None resulted from viral hepatitis.There were no statistical differences in age, sex, PTU dose, or T4 and T3 levels at ini

38、tial diagnosis between patients with and without hepatic injury. LFT normalized in all patients between 16 and 145 (72.8 +/46.4) days after the PTU withdrawal. CONCLUSIONS: Symptomatic hepatic injury develops usually within the first few months of PTU administration with rare frequency, but its clin

39、ical course is relatively benign once the drug is withdrawn. However, it may be difficult to predict its development, so all patients should be monitored for rise in LFTs at regular intervals, especially during the early period.70: Endocr Pract. 2000 Sep-Oct;6(5):367-9.Related Articles,LinksaAbnorma

40、l results of liver function tests in patients with Graves' disease.Biscoveanu M, Hasinski S.Division of Endocrinology and Metabolism, Department of Medicine, HahnemannJniversityHospital, Philadelphia,Pennsylvania 19102, USA.OBJECTIVE: To determine the frequency of liver dysfunction in patients w

41、ith hyperthyroidism. METHODS: We analyzed the clinical records of 30 consecutive patients with Graves' disease to identify thespectrumof abnormal results of liver function tests. The values for alkaline phosphatase (AP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma -gl

42、utamyltransferase (GGT), and total bilirubin were examined. RESULTS: The frequencies of increased levels of AP, AST, ALT, GGT, and bilirubin in the current study group were similar to but somewhat lower than those reported in previous studies. Of the 30 study patients, 11 (37%) had at least one abno

43、rmal result of a liver function test. All 30 patients in the study had determinations of AP (not fractionated), of which 10 values (33%) were above normal (range, 124 to 283 U/L). Of the 30 patients who had determinations of AST, 5 (17%) had increased values that ranged from 36 to 71 U/L. Six of the

44、 23 patients (26%) with determinations of ALT had increased values that ranged from 45 to 157 U/L. Of the時(shí)間：二 O 二一年七月二十九日時(shí)間：二 O 二一年七月二十九日25 patients who had measurements of GGT, 6 had above normal results (range, 69 to 331 U/L). In addition, 2 of the 24 patients (8%) with determinations of totalbili

45、rubin had increased levels. CONCLUSION: These findings indicate that abnormal results of liver function tests are common in patients with hyperthyroidism and make the diagnosis of concomitant, unrelated liver disease difficult until the euthyroid state has been established.: J R Soc Health. 1999 Jun

46、;119(2):117-20.Related Articles,LinksLessons to be learned: a case study approach: severe hyponatraemia induced by primary hypothyroidism and associated with possible increased hepatic sensitivity to thyroxine WordStrment.Olukoga A, Horsman G, Stewart F.Department of Clinical Biochemistry, Hope Hosp

47、ital, Salford, Manchester. AOlukogaThe case is presented of a 74 year-old woman who was admitted with severe hypo-osmolar hyponatraemia associated with inappropriately raised urinary osmolality, and who was subsequently discovered to have primary hypothyroidism. A normal serum sodium concentration w

48、as restored by means of judicious fluid restriction and thyroid hormone WordStrment. Low dose thyroxine therapy led to rapid but modest increases in the serum activities of alanine aminotransferase (ALT) and alkaline phosphatase (ALP); both returned to normal over a period of three weeks. These sub-

49、clinical enzyme changes may indicate tissue 'hyperthyroidism' and in this case, the fact that they occurred acutely at only low doses of thyroxine possibly suggests an increased hepatic sensitivity to the hormone.104: Scand J Gastroenterol. 1999 Jun;34(6):618-22.Related Articles,LinksLiver v

50、olume, portal vein flow, and clearance of indocyanine green and antipyrine in hyperthyroidism before and after antithyroid treatment.Andersen V, Sonne J, Court-Payen M, Sletting S, Prip A, Molholm Hansen J.Dept. of Endocrinology and Internal Medicine, HerlevHospital, Denmark.BACKGROUND: The aim of t

51、he study was to examine livervolume, portal vein flow, and indocyanine green (ICG) and antipyrine clearance in hyperthyroidism before and after antithyroid drug treatment. METHODSL:iver volume and blood flow in the portal vein were investigated in nine fasting patients with hyperthyroidism bymeans o

52、fcomputed tomography scan and Doppler ultrasound, respectively. ICG clearance was estimated by bolus injection of ICG (0.5 mg/kg body weight) and antipyrine clearance with a one-sample technique. All patientswere investigated before and after 3 months of antithyroid treatment, when euthyroidism had

53、been achieved. The Wilcoxon matched-pairs test was used for statistical analysis. RESULTS:The median liver volume increased by 238 (155-289) ml (median, 95% confidence interval), corresponding to 19%, and the weight by 5.0 (0.0-8.0) kg (8%), and the antipyrine clearance decreased by 8 (3.1-34.4) ml/

54、min (16%). These changes were all significant (P < 0.05). The relation betweenliver volume and body weight increased from 19.9 (16.5-23.7) ml/kg to 21.4 (17.1-21.9) ml/kg (P = 0.11). The liver blood flow as estimated by ICG clearance and Doppler ultrasound was not altered significantly after the

55、treatment period (P = 0.07 and 0.77, respectively). CONCLUSIONS: The liver volume increased by 19% in nine hyperthyroid patients during treatment with antithyroids. Antipyrine clearance was reduced by 16%, whereas liver blood flow, as estimated by ICG clearance and Doppler ultrasound examination of

56、portal vein flow, was not significantly altered. A differential regulation of liver volume and oxidative metabolic capacity in hyperthyroidism was seen.參考文獻(xiàn)：1: Gurlek A, Cobankara V, Bayraktar M. Liver tests in hyperthyroidism:effect of antithyroid therapy.J ClinGastroenterol 1997 Apr;24(3):180-32:

57、Huang MJ, Li KL, Wei JS, Wu SS, Fan KD, Liaw YF. Sequential liver and bone biochemical changes in hyperthyroidism: prospective controlled follow-up study.Am J Gastroenterol 1994 Jul;89(7):1071-63: Sheridan P . Thyroid hormones and the liver.Clin Gastroenterol 1983 Sep;12(3):797-8184: Babb RR. Associations between diseases of the thyroid and the liver.Am J Gastroenterol 1984 May;79(5):421-35: Smith AC, Berman ML, James RC, Harbison RD.Characterization of hyperthyroidism enhancement of halothane-induced hepatotoxi